Secretome versus PRP injections to improve hair density in androgenetic alopecia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, controlled, interventional Phase 1–2 trial comparing intradermal secretome injections with intradermal platelet-rich plasma (PRP) injections for androgenetic alopecia. Adults aged 25–59 with male pattern (Hamilton-Norwood II–VI) or female pattern (Ludwig I–III) hair loss are randomized to one of the two injection arms. Hair density and the terminal-to-vellus hair ratio are measured by trichoscopy/dermoscopy before and after a series of treatments to quantify changes. The trial is conducted at Prof. dr. I.G.N.G. Ngoerah Central General Hospital in Denpasar, Bali with safety monitoring appropriate for early-phase interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
* Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
* Female patients who are not currently pregnant or breastfeeding.
* Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
* Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
* Patients who are proficient in Indonesian and willing to provide written informed consent.

Exclusion Criteria:

* Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
* Patients presenting with types of hair loss other than androgenetic alopecia.
* Patients currently undergoing therapy with 5-alpha reductase inhibitors.
* Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
* Patients with active infections and/or active dermatitis on the scalp.
* Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
* History of hypertrophic scarring or blood clotting (coagulation) disorders.
* Patients unable to complete the research procedures in their entirety.

Where it's running

• Prof. dr. I.G.N.G. Ngoerah Central General Hospital
  Denpasar, Bali, Indonesia Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PP405 0.05% topically applied gel for adult men with pattern hair loss

  A topical gel called PP405 is being tested in adult men with androgenetic alopecia to see if it can help with hair growth and is safe over a year.

  Recruiting at 34 sites Phase 2/3 Pelage Pharmaceuticals, Inc. · Birmingham, Alabama and 62 other locations · NCT07819435

• EPI-001 for androgenetic alopecia in adults

  This early-phase study tests autologous dermal papilla cell therapy (EPI-001) to see if it is safe and can help hair grow in people with androgenetic alopecia.

  Recruiting Phase 1/2 Epibiotech · Seoul, Seoul · NCT07618195

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• Fractional laser plus exosome vs. laser plus placebo for androgenetic alopecia

  This study tests whether adding a human umbilical cord mesenchymal stem cell exosome solution to fractional laser therapy helps men with androgenetic alopecia grow more hair than laser therapy with a placebo.

  Recruiting Chang Gung Memorial Hospital · Taoyuan, Taoyuan · NCT07248410

• Once-daily 5% minoxidil foam for female pattern hair loss

  This will try once-daily 5% minoxidil foam to see if it increases hair count in adult women with androgenetic alopecia compared with a placebo.

  Recruiting Phase 3 Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Beijing · NCT07080931

• CKD-843 for male pattern baldness: a new treatment in Phase 3

  We’re testing CKD-843 in men aged 18–50 with androgenetic alopecia to see if it helps hair loss over 12 months.

  Recruiting Phase 3 Chong Kun Dang Pharmaceutical · Seoul · NCT06916793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.